Lupin to partner pharma firms for adoption of its long-acting injectable platform PrecisionSphere

The company said PrecisionSphere has demonstrated efficacy and safety in delivering medicines and is ready for commercial use following the US regulator’s approval of the first product developed with the platform.

“Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles, whether in development or already on the market, especially those that could benefit from longer-acting formulations,” the company said in an exchange filing.

PrecisionSphere, according to Lupin, helps fix major compliance problems that can make drugmakers lose money and cause treatments to fail.

Unlike regular LAI technologies that create uneven particle sizes, this platform makes medicines with uniform size, shape, and properties, which makes them easier to inject. It also helps keep drug levels steady, releasing the medicine evenly over several weeks or months.

Commenting on the development, Dr. Shahin Fesharaki, Chief Scientific Officer, Lupin, said, “PrecisionSphere reflects our commitment to innovation and leverages our regulatory expertise, scalable manufacturing capabilities, and flexible collaboration models to lower entry barriers for developing LAIs. This allows partners to efficiently bring advanced LAIs to market across various therapeutic areas and potentially extend the patent life of their products.”

In a separate filing, on Wednesday, October 8, the pharmaceutical major announced its plans for a new state-of-the-art pharmaceutical manufacturing plant in Coral Springs, a significant step in safeguarding the health and safety of Florida families and the nation.

Early in October, Lupin said it had launched a generic diabetes medication in the US market.

It has launched Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pen in the US, the Mumbai-based drug maker said in a statement. The product is bioequivalent to Novo Nordisk Inc.'s Victoza injection, it added.

Lupin share price

Shares of Lupin gained as much as 4.12% to touch an intraday high of ₹1,984.20 apiece on Thursday, October 9. At close, the shares settled 2.59% higher at ₹1,955 per equity share on the National Stock Exchange (NSE).

Over the past five trading sessions, the company’s shares have declined 2.05%, and further dropped 0.12% over the past month. On the contrary, the stock has jumped 1.84% in the last six months and has declined 17.33% year-to-date.

Lupin’s shares reached a 52-week high of ₹2,402.90 on January 2, 2025, and a 52-week low of ₹1,795.20 on April 7, 2025. As of October 9, the company’s market capitalisation stood at ₹89,296.16 crore.